SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, will participate in two panel discussions, at the 2018 Citi Biotech Conference in Boston. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will represent Mirati at the event.
- "Targeted Therapies Oncology - Aiming for the Bull's Eye" Panel on Wednesday, September 5th at 3:15 p.m. ET/12:15 p.m. PT
- "Landscape in Immuno-Oncology and Bi-Specific Antibodies" Panel on Thursday, September 6th at 9:00 a.m. ET/ 6:00 a.m. PT
The webcasts will be available through the "Investors" section of www.mirati.com, and a replay of the webcasts will be made available for 90 days following the event.
About Mirati Therapeutics
Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic, epigenetic and immunological promoters of cancer. Our precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients who we believe would be most likely to benefit from targeted drug treatment. In immuno-oncology, we are advancing clinical programs where our product candidates have the potential to improve the immune environment of tumor cells and may enhance and expand the efficacy of existing cancer immunotherapy medicines when given in combination. Our pre-clinical programs include potentially first-in-class and best-in-class product candidates specifically designed to address mutations and tumors where few treatment options exist. We approach each of our discovery and development programs with a singular focus: to translate our deep understanding of the molecular drivers of cancer into better therapies and better outcomes for patients. For more information, visit www.mirati.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/mirati-therapeutics-to-participate-in-oncology-panels-at-the-2018-citi-biotech-conference-300704377.html